NuCana plc American Depositary Share

NuCana plc American Depositary Share

NCNA Stock Report Card





Score: 100/100


NCNA returned 49.12% in the last 12 months. Based on the other stocks in its sector with an average return of -5.67%, its performance is above average giving it a grade of 100 of 100.


Score: 94/100


4 analysts offer 12-month price forecasts for NCNA. Together, they have an average target of 0, the most optimistic forecast put NCNA at 0 within 12-months and the most pessimistic has NCNA at 0.


Score: 64/100


NCNA had a bullish sentiment score of 64.44% across Twitter and StockTwits over the last 12 months. It had an average of 2.50 posts, 0.00 comments, and 0.00 likes per day.


Score: 50/100


NCNA receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.


Score: 10/100


NCNA has missed earnings 6 times in the last 20 quarters.


Score: 10/100


Out of the last 20 quarters, NCNA has had 0 profitable quarters and has increased their profits year over year on 0 of them.


Score: 54/100


NCNA has had a higher than average amount of volatility over the last 12 months giving it a grade of 53 of 100.

NuCana plc American Depositary Share Summary

Nasdaq / NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Power up your portfolio

Build a portfolio of the best stocks

Pluto makes it easy to build investing strategies and automate your portfolio
pluto logo
Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.